Ovascience Insider Christopher Bleck Acquires 2,000 Shares (OVAS)
Ovascience (NASDAQ:OVAS) Insider Christopher Bleck purchased 2,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, September 11th. The shares were purchased at an average cost of $11.15 per share, for a total transaction of $22,300.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Separately, analysts at Wedbush initiated coverage on shares of Ovascience (NASDAQ:OVAS) in a research note to investors on Wednesday, September 4th. They set an “outperform” rating and a $20.00 price target on the stock.
Shares of Ovascience (NASDAQ:OVAS) traded down 6.67% on Thursday, hitting $10.22. 133,252 shares of the company’s stock traded hands. Ovascience has a 52 week low of $7.50 and a 52 week high of $16.00. The stock has a 50-day moving average of $12.32 and a 200-day moving average of $11.96. The company’s market cap is $172.6 million.
Ovascience (NASDAQ:OVAS) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.36) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.28) by $0.08. Analysts expect that Ovascience will post $-1.41 EPS for the current fiscal year.
OvaScience, Inc, is a life science company developing products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.